Tedizolid Phosphate

Identification

Name
Tedizolid Phosphate
Accession Number
DB09042
Type
Small Molecule
Groups
Approved
Description

Tedizolid Phosphate is an oxazolidinone-class antibiotic prodrug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of several Gram-positive bacteria. Following administration via oral or intravenous route, tedizolid phosphate prodrug is converted by plasma phosphatases to its active moiety, tedizolid. Once activated, tedizolid exerts its bacteriostatic microbial activity through inhibition of protein synthesis by binding to the 50S ribosomal subunit of susceptible bacteria. Tedizolid is an effective and potent alternative to linezolid for the treatment of patients with Gram-positive ABSSSI due to MRSA or MSSA. Increased potency allows for once daily dosing with reduced total dosages, improving the side effect profile of this drug. Of note, the minimum inhibitory concentrations of tedizolid appear to be largely unaffected by the chloramphenicol-florfenicol resistance (cfr) gene, which has been implicated in a number of published linezolid-resistant organism outbreaks.

Structure
Thumb
Synonyms
  • [(5R)-3-{3-fluoro-4-[6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methyl dihydrogen phosphate
  • Tedizolid
  • Torezolid Phosphate
External IDs
TR 701 / TR-701 / TR-701 FA / TR-701FA / TR701
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SivextroTablet200 mgOralMerck Ltd.Not applicableNot applicableCanada
SivextroInjection, powder, lyophilized, for solution200 mg/4mLIntravenousMerck Sharp & Dohme Limited2014-06-20Not applicableUs
SivextroInjection, powder, for solution200 mgIntravenousMerck Sharp & Dohme Limited2015-03-23Not applicableEu
SivextroPowder, for solution200 mgIntravenousMerck Ltd.Not applicableNot applicableCanada
SivextroTablet, film coated200 mgOralMerck Sharp & Dohme Limited2015-03-23Not applicableEu
SivextroTablet, film coated200 mg/1OralMerck Sharp & Dohme Limited2014-06-20Not applicableUs
SivextroInjection, powder, for solution200 mgIntravenousMerck Sharp & Dohme Limited2015-03-23Not applicableEu
Categories
UNII
O7DRJ6R4DW
CAS number
856867-55-5
Weight
Average: 450.323
Monoisotopic: 450.08529742
Chemical Formula
C17H16FN6O6P
InChI Key
QCGUSIANLFXSGE-GFCCVEGCSA-N
InChI
InChI=1S/C17H16FN6O6P/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(30-17(24)25)9-29-31(26,27)28/h2-7,12H,8-9H2,1H3,(H2,26,27,28)/t12-/m1/s1
IUPAC Name
{[(5R)-3-{3-fluoro-4-[6-(2-methyl-2H-1,2,3,4-tetrazol-5-yl)pyridin-3-yl]phenyl}-2-oxo-1,3-oxazolidin-5-yl]methoxy}phosphonic acid
SMILES
CN1N=NC(=N1)C1=CC=C(C=N1)C1=CC=C(C=C1F)N1C[[email protected]](COP(O)(O)=O)OC1=O

Pharmacology

Indication

Tedizolid Phosphate is an oxazolidinone antibacterial drug indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

After conversion to its active form by phosphatases, tedizolid exerts its antibacterial activity through inhibition of protein synthesis by binding to the 50S ribosomal subunit of susceptible Gram-positive bacteria. Cross-resistance between other non-oxazolidinone antibacterial drugs is unlikely as it inhibits bacterial protein synthesis through a different mechanism.

Absorption

Peak plasma tedizolid concentrations are achieved within approximately 3 hours following oral administration under fasting conditions or at the end of the 1 hour intravenous infusion of tedizolid phosphate. The absolute bioavailability is approximately 91% and no dosage adjustment is necessary between intravenous and oral administration. Oral tedizolid phosphate may be administered with or without food as total systemic exposure is unchanged between fasted and fed conditions.

Volume of distribution

Mean steady-state volume of distribution after 200 mg intravenous infusion is between 67-80 L

Protein binding

Binding to plasma protein is between 70-90%

Metabolism

Tedizolid phosphate is a prodrug that is converted by phosphatases to tedizolid, it's microbiologically active form. There are no other significant circulating metabolites beyond tedizolid which accounts for approximately 95% of the AUC. It is also unlikely to be metabolized by CYP450 enzymes in the liver.

Route of elimination

Tedizolid is excreted in feces as a non-circulating and microbiologically inactive sulfate conjugate.

Half life

12 hours

Clearance

Clearance of a single oral 200 mg dose is 6.9 L/hr, while steady state clearance is 8.4 L/hr

Toxicity

The most commonly reported adverse effects were nausea, vomiting, diarrhea, nausea, and dizziness. Other reactions that occurred during clinical trials at a rate less than 2% include anemia, tachycardia, blurred vision, oral candidiasis, colitis, decreased white blood cell count, vulvovaginal mycotic infection, paresthesia, hypertension, and urticaria. There are no adequate studies to confirm that tedizolid phosphate is safe to use during pregnancy and should be avoided as it was shown to produce fetal developmental toxicities in mice, rats, and rabbits.

Affected organisms
  • Bacteria
  • Streptococcus pyogenes
  • Streptococcus agalactiae
  • Staphylococcus aureus
  • Enterococcus faecalis
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololTedizolid Phosphate may increase the hypertensive activities of Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Acetophenazine.Approved
AlmotriptanTedizolid Phosphate may increase the serotonergic activities of Almotriptan.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Amisulpride.Approved, Investigational
AmitriptylineTedizolid Phosphate may increase the serotonergic activities of Amitriptyline.Approved
AmoxapineTedizolid Phosphate may increase the serotonergic activities of Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Amperozide.Experimental
AmphetamineTedizolid Phosphate may increase the hypertensive activities of Amphetamine.Approved, Illicit, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Aripiprazole.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Asenapine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Azaperone.Investigational, Vet Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Tedizolid Phosphate.Investigational
BenperidolThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Benperidol.Approved, Investigational
BenzphetamineTedizolid Phosphate may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BifeprunoxThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Bifeprunox.Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Brexpiprazole.Approved, Investigational
BromocriptineTedizolid Phosphate may increase the serotonergic activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Bromperidol.Approved, Investigational
BucindololTedizolid Phosphate may increase the hypertensive activities of Bucindolol.Investigational
BuspironeTedizolid Phosphate may increase the serotonergic activities of Buspirone.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Butaperazine.Experimental
CabergolineTedizolid Phosphate may increase the serotonergic activities of Cabergoline.Approved
CariprazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Cariprazine.Approved, Investigational
CeliprololTedizolid Phosphate may increase the hypertensive activities of Celiprolol.Approved, Investigational
ChlorphentermineTedizolid Phosphate may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CitalopramTedizolid Phosphate may increase the serotonergic activities of Citalopram.Approved
ClenbuterolTedizolid Phosphate may increase the hypertensive activities of Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineTedizolid Phosphate may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Clopenthixol.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Clozapine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Cyamemazine.Approved
CyclobenzaprineTedizolid Phosphate may increase the serotonergic activities of Cyclobenzaprine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Dapiprazole.Approved
DesipramineTedizolid Phosphate may increase the serotonergic activities of Desipramine.Approved, Investigational
DesvenlafaxineTedizolid Phosphate may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DextromethorphanTedizolid Phosphate may increase the serotonergic activities of Dextromethorphan.Approved
DihydroergotamineTedizolid Phosphate may increase the serotonergic activities of Dihydroergotamine.Approved, Investigational
DixyrazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Dixyrazine.Experimental
DobutamineTedizolid Phosphate may increase the hypertensive activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Tedizolid Phosphate.Approved, Investigational
DopamineTedizolid Phosphate may increase the hypertensive activities of Dopamine.Approved
DoxepinTedizolid Phosphate may increase the serotonergic activities of Doxepin.Approved, Investigational
DroperidolThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Droperidol.Approved, Vet Approved
DuloxetineTedizolid Phosphate may increase the serotonergic activities of Duloxetine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ecopipam.Investigational
EletriptanTedizolid Phosphate may increase the serotonergic activities of Eletriptan.Approved, Investigational
EpanololTedizolid Phosphate may increase the hypertensive activities of Epanolol.Experimental
EphedrineTedizolid Phosphate may increase the hypertensive activities of Ephedrine.Approved
EpinephrineTedizolid Phosphate may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateTedizolid Phosphate may increase the serotonergic activities of Ergoloid mesylate.Approved
ErgonovineTedizolid Phosphate may increase the serotonergic activities of Ergonovine.Approved
ErgotamineTedizolid Phosphate may increase the serotonergic activities of Ergotamine.Approved
EscitalopramTedizolid Phosphate may increase the serotonergic activities of Escitalopram.Approved, Investigational
EtilefrineTedizolid Phosphate may increase the hypertensive activities of Etilefrine.Withdrawn
FencamfamineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolTedizolid Phosphate may increase the hypertensive activities of Fenoterol.Approved, Investigational
FenozoloneTedizolid Phosphate may increase the hypertensive activities of Fenozolone.Experimental
FentanylTedizolid Phosphate may increase the serotonergic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FluanisoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fluanisone.Experimental
FluoxetineTedizolid Phosphate may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Fluspirilene.Approved, Investigational
FluvoxamineTedizolid Phosphate may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FrovatriptanTedizolid Phosphate may increase the serotonergic activities of Frovatriptan.Approved, Investigational
GranisetronGranisetron may increase the serotonergic activities of Tedizolid Phosphate.Approved, Investigational
HaloperidolThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Haloperidol.Approved
HydroxyamphetamineTedizolid Phosphate may increase the hypertensive activities of Hydroxyamphetamine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Iloperidone.Approved
ImipramineTedizolid Phosphate may increase the serotonergic activities of Imipramine.Approved
IsocarboxazidTedizolid Phosphate may increase the serotonergic activities of Isocarboxazid.Approved
IsoprenalineTedizolid Phosphate may increase the hypertensive activities of Isoprenaline.Approved, Investigational
IsoxsuprineTedizolid Phosphate may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
LabetalolTedizolid Phosphate may increase the hypertensive activities of Labetalol.Approved
LevomilnacipranTedizolid Phosphate may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
LinezolidTedizolid Phosphate may increase the serotonergic activities of Linezolid.Approved, Investigational
LipegfilgrastimTedizolid Phosphate may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LithiumTedizolid Phosphate may increase the serotonergic activities of Lithium.Approved
LorcaserinTedizolid Phosphate may increase the serotonergic activities of Lorcaserin.Approved
LoxapineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Loxapine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Lurasidone.Approved, Investigational
MaprotilineTedizolid Phosphate may increase the serotonergic activities of Maprotiline.Approved, Investigational
MefenorexTedizolid Phosphate may increase the hypertensive activities of Mefenorex.Experimental
MelperoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Melperone.Approved, Investigational
MephentermineTedizolid Phosphate may increase the hypertensive activities of Mephentermine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Mesoridazine.Approved, Investigational
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Tedizolid Phosphate.Approved, Investigational, Withdrawn
MetaraminolTedizolid Phosphate may increase the hypertensive activities of Metaraminol.Approved, Investigational
MethadoneTedizolid Phosphate may increase the serotonergic activities of Methadone.Approved
MethamphetamineTedizolid Phosphate may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethotrimeprazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Methotrimeprazine.Approved, Investigational
MethoxamineTedizolid Phosphate may increase the hypertensive activities of Methoxamine.Approved, Investigational
MetoclopramideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Metoclopramide.Approved, Investigational
MidodrineTedizolid Phosphate may increase the hypertensive activities of Midodrine.Approved
MilnacipranTedizolid Phosphate may increase the serotonergic activities of Milnacipran.Approved, Investigational
MirtazapineTedizolid Phosphate may increase the serotonergic activities of Mirtazapine.Approved
MoclobemideTedizolid Phosphate may increase the serotonergic activities of Moclobemide.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Moperone.Experimental
MosapramineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Mosapramine.Experimental
NaratriptanTedizolid Phosphate may increase the serotonergic activities of Naratriptan.Approved, Investigational
NefazodoneTedizolid Phosphate may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NorepinephrineTedizolid Phosphate may increase the hypertensive activities of Norepinephrine.Approved
NortriptylineTedizolid Phosphate may increase the serotonergic activities of Nortriptyline.Approved
NylidrinTedizolid Phosphate may increase the hypertensive activities of Nylidrin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Olanzapine.Approved, Investigational
OndansetronOndansetron may increase the serotonergic activities of Tedizolid Phosphate.Approved
OrciprenalineTedizolid Phosphate may increase the hypertensive activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Osanetant.Investigational
OxymetazolineTedizolid Phosphate may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxypertineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Oxypertine.Experimental
PaliperidoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Tedizolid Phosphate.Approved, Investigational
ParoxetineTedizolid Phosphate may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Penfluridol.Experimental
PerazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Perphenazine.Approved
PethidineTedizolid Phosphate may increase the serotonergic activities of Pethidine.Approved
PhenelzineTedizolid Phosphate may increase the serotonergic activities of Phenelzine.Approved
PhenmetrazineTedizolid Phosphate may increase the hypertensive activities of Phenmetrazine.Approved, Illicit
PhentermineTedizolid Phosphate may increase the hypertensive activities of Phentermine.Approved, Illicit
PhenylephrineTedizolid Phosphate may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineTedizolid Phosphate may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Tedizolid Phosphate.Approved
PimozideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Pipotiazine.Approved, Investigational
PrenalterolTedizolid Phosphate may increase the hypertensive activities of Prenalterol.Experimental
ProcarbazineTedizolid Phosphate may increase the serotonergic activities of Procarbazine.Approved, Investigational
ProcaterolTedizolid Phosphate may increase the hypertensive activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Prochlorperazine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Promazine.Approved, Vet Approved
PromethazineTedizolid Phosphate may increase the serotonergic activities of Promethazine.Approved, Investigational
PropericiazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Propericiazine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Prothipendyl.Investigational
ProtriptylineTedizolid Phosphate may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineTedizolid Phosphate may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Quetiapine.Approved
RacepinephrineTedizolid Phosphate may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Raclopride.Investigational
RasagilineTedizolid Phosphate may increase the serotonergic activities of Rasagiline.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Reserpine.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ritanserin.Investigational
RitodrineTedizolid Phosphate may increase the hypertensive activities of Ritodrine.Approved, Investigational
RizatriptanTedizolid Phosphate may increase the serotonergic activities of Rizatriptan.Approved
SelegilineTedizolid Phosphate may increase the serotonergic activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineTedizolid Phosphate may increase the serotonergic activities of Sertraline.Approved
SulpirideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Sultopride.Experimental
SumatriptanTedizolid Phosphate may increase the serotonergic activities of Sumatriptan.Approved, Investigational
SynephrineTedizolid Phosphate may increase the hypertensive activities of Synephrine.Experimental
TapentadolTedizolid Phosphate may increase the serotonergic activities of Tapentadol.Approved
TerbutalineTedizolid Phosphate may increase the hypertensive activities of Terbutaline.Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Tetrahydropalmatine.Investigational
TetryzolineTedizolid Phosphate may increase the hypertensive activities of Tetryzoline.Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Tiapride.Approved, Investigational
TramadolTedizolid Phosphate may increase the serotonergic activities of Tramadol.Approved, Investigational
TramazolineTedizolid Phosphate may increase the hypertensive activities of Tramazoline.Investigational
TranylcypromineTedizolid Phosphate may increase the serotonergic activities of Tranylcypromine.Approved, Investigational
TrazodoneTedizolid Phosphate may increase the serotonergic activities of Trazodone.Approved, Investigational
TretoquinolTedizolid Phosphate may increase the hypertensive activities of Tretoquinol.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Triflupromazine.Approved, Vet Approved
TrimipramineTedizolid Phosphate may increase the serotonergic activities of Trimipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Tedizolid Phosphate.Approved, Investigational
TyramineTedizolid Phosphate may increase the hypertensive activities of Tyramine.Investigational, Nutraceutical
VenlafaxineTedizolid Phosphate may increase the serotonergic activities of Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Veralipride.Experimental
VilazodoneTedizolid Phosphate may increase the serotonergic activities of Vilazodone.Approved
VortioxetineTedizolid Phosphate may increase the serotonergic activities of Vortioxetine.Approved, Investigational
ZiprasidoneThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Ziprasidone.Approved
ZolmitriptanTedizolid Phosphate may increase the serotonergic activities of Zolmitriptan.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, Prokocimer P: Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014 Aug;42(8):1275-84. doi: 10.1124/dmd.113.056697. Epub 2014 May 29. [PubMed:24875463]
  2. Michalska K, Karpiuk I, Krol M, Tyski S: Recent development of potent analogues of oxazolidinone antibacterial agents. Bioorg Med Chem. 2013 Feb 1;21(3):577-91. doi: 10.1016/j.bmc.2012.11.036. Epub 2012 Dec 5. [PubMed:23273607]
  3. Rybak JM, Roberts K: Tedizolid Phosphate: a Next-Generation Oxazolidinone. Infect Dis Ther. 2015 Feb 24. [PubMed:25708156]
  4. Gras J: Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. Drugs Today (Barc). 2014 Nov;50(11):729-37. doi: 10.1358/dot.2014.50.11.2233783. [PubMed:25525633]
  5. Flanagan S, Fang E, Munoz KA, Minassian SL, Prokocimer PG: Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy. 2014 Sep;34(9):891-900. doi: 10.1002/phar.1458. Epub 2014 Jul 3. [PubMed:24989138]
External Links
KEGG Drug
D09686
PubChem Compound
11476460
PubChem Substance
310264990
ChemSpider
9651289
BindingDB
50017198
ChEBI
83326
ChEMBL
CHEMBL2105669
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Tedizolid
ATC Codes
J01XX11 — Tedizolid
AHFS Codes
  • 08:12.28.24 — Oxazolidinones
FDA label
Download (378 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHepatic Impairment1
1CompletedBasic ScienceBacterial Infections3
1CompletedBasic ScienceHealthy Volunteers3
1CompletedOtherHealthy Volunteers3
1CompletedTreatmentImpaired Renal Function1
1CompletedTreatmentSkin Diseases, Bacterial1
1Not Yet RecruitingTreatmentGram-Positive Infections1
1RecruitingOtherDiabetes Mellitus (DM) / Healthy Volunteers / Wound Infections1
1RecruitingTreatmentInfections, Gram-Positive Bacterial1
2CompletedNot AvailableCellulitis / Erysipelas / Major Cutaneous Abscess1
2CompletedTreatmentSkin Diseases, Bacterial / Skin Diseases, Infectious1
2RecruitingTreatmentBone and Joint Infections1
3CompletedTreatmentBacterial Infections1
3CompletedTreatmentSkin Diseases, Infectious1
3CompletedTreatmentSkin and Subcutaneous Tissue Bacterial Infections2
3Not Yet RecruitingTreatmentAcute Bacterial Skin and Skin Structure Infections1
3RecruitingTreatmentPneumonia1
3RecruitingTreatmentSkin Diseases, Bacterial / Skin Diseases, Infectious1
4CompletedHealth Services ResearchBMI >30 kg/m21
Not AvailableNot Yet RecruitingTreatmentProsthetic Joint Infection1
Not AvailableRecruitingNot AvailableAbscesses / Cellulitis / Erysipelas / Wound Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous200 mg
Injection, powder, lyophilized, for solutionIntravenous200 mg/4mL
Powder, for solutionIntravenous200 mg
TabletOral200 mg
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral200 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7816379No2008-02-232028-02-23Us
US8420676No2008-02-232028-02-23Us
US8426389No2010-12-312030-12-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP4.89ChEMBL
Predicted Properties
PropertyValueSource
Water Solubility0.608 mg/mLALOGPS
logP0.82ALOGPS
logP1.97ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)1.35ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area152.79 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity125.93 m3·mol-1ChemAxon
Polarizability41.46 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Phenylpyridines
Direct Parent
Phenylpyridines
Alternative Parents
Fluorobenzenes / Monoalkyl phosphates / Oxazolidinones / Aryl fluorides / Tetrazoles / Carbamate esters / Heteroaromatic compounds / Organic carbonic acids and derivatives / Azacyclic compounds / Oxacyclic compounds
show 6 more
Substituents
3-phenylpyridine / Fluorobenzene / Halobenzene / Monoalkyl phosphate / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Organic phosphoric acid derivative / Oxazolidinone / Phosphoric acid ester
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, carbamate ester, tetrazoles, pyridines, ring assembly, oxazolidinone (CHEBI:83326)

Drug created on April 27, 2015 16:15 / Updated on May 21, 2018 17:37